PMID- 36480832
OWN - NLM
STAT- MEDLINE
DCOM- 20221215
LR  - 20221215
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 51
IP  - 12
DP  - 2022 Dec 8
TI  - [The diagnostic value of CCNB3 and BCOR expression in BCOR-CCNB3 sarcoma].
PG  - 1235-1239
LID - 10.3760/cma.j.cn112151-20220920-00791 [doi]
AB  - Objective: To investigate the diagnostic value of expression of CCNB3 and BCOR in 
      BCOR-CCNB3 sarcoma (BCS). Methods: Fifteen cases of BCS confirmed by fluorescence 
      in situ hybridization (FISH) and/or reverse transcription-polymerase chain 
      reaction (RT-PCR) from January 2014 to October 2021 at Beijing Jishuitan Hospital 
      were collected. Immunohistochemical EnVision method was used to detect the 
      expression of CCNB3 and BCOR in 15 cases of BCS and in 65 non-BCS tumors (54 
      cases of Ewing's sarcoma, 5 cases of CIC rearranged sarcoma, 4 cases of synovial 
      sarcoma, 1 case of mesenchymal chondrosarcoma and 1 case of soft tissue clear 
      cell sarcoma). Results: Immunohistochemical staining for CCNB3 revealed strongly 
      diffuse nuclear staining in 14 of 15 (14/15) BCS cases, whereas none of the 65 
      non-BCS tumors showed any staining. Immunohistochemical staining for BCOR showed 
      strongly diffuse nuclear staining in 11 (11/14) BCS cases; seven of the 65 (7/65, 
      10.8%) non-BCS tumors showed variable staining (five cases of Ewing sarcoma, one 
      cases of synovial sarcoma, and one case of mesenchymal chondrosarcoma). The 
      sensitivity and specificity of CCNB3 in diagnosing BCS were 93.3% and 100% and 
      these of BCOR were 78.6% and 89.2%, respectively. Conclusions: CCNB3 is a highly 
      sensitive and specific marker for BCS.The antibody may help screening BCS.
FAU - Li, L
AU  - Li L
AD  - Department of Pathology, Beijing Jishuitan Hospital, Fourth Medical College of 
      Peking University, Beijing 100035, China.
FAU - Zhang, M
AU  - Zhang M
AD  - Department of Pathology, Beijing Jishuitan Hospital, Fourth Medical College of 
      Peking University, Beijing 100035, China.
FAU - Sun, X Q
AU  - Sun XQ
AD  - Department of Pathology, Beijing Jishuitan Hospital, Fourth Medical College of 
      Peking University, Beijing 100035, China.
FAU - Zhang, T T
AU  - Zhang TT
AD  - Department of Pathology, Beijing Jishuitan Hospital, Fourth Medical College of 
      Peking University, Beijing 100035, China.
FAU - Ding, Y
AU  - Ding Y
AD  - Department of Pathology, Beijing Jishuitan Hospital, Fourth Medical College of 
      Peking University, Beijing 100035, China.
LA  - chi
GR  - Z171100001017134/Beijing Science and Technology Project/
GR  - XKXX201811/Beijing Jishuitan Hospital Nova Program/
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (CCNB3 protein, human)
RN  - 0 (Cyclin B)
RN  - 0 (BCOR protein, human)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Repressor Proteins)
SB  - IM
MH  - Humans
MH  - *Sarcoma, Synovial/diagnosis/genetics
MH  - In Situ Hybridization, Fluorescence
MH  - Cyclin B/genetics
MH  - Proto-Oncogene Proteins/genetics
MH  - Repressor Proteins/genetics
EDAT- 2022/12/09 06:00
MHDA- 2022/12/15 06:00
CRDT- 2022/12/08 22:12
PHST- 2022/12/08 22:12 [entrez]
PHST- 2022/12/09 06:00 [pubmed]
PHST- 2022/12/15 06:00 [medline]
AID - 10.3760/cma.j.cn112151-20220920-00791 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2022 Dec 8;51(12):1235-1239. doi: 
      10.3760/cma.j.cn112151-20220920-00791.